Illumina, Inc. (NASDAQ:ILMN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received a consensus recommendation of “Moderate Buy” from the twenty research firms that are covering the company, Marketbeat reports. Eight analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $165.95.

A number of research analysts recently issued reports on ILMN shares. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Wednesday, August 28th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. TD Cowen lifted their price target on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. UBS Group upped their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, StockNews.com initiated coverage on shares of Illumina in a research note on Thursday, August 29th. They set a “buy” rating on the stock.

Hedge Funds Weigh In On Illumina

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina during the second quarter valued at $34,000. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares during the period. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Illumina in the second quarter worth approximately $61,000. Finally, Private Trust Co. NA raised its holdings in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

Shares of ILMN stock opened at $135.21 on Thursday. The company has a market capitalization of $21.44 billion, a P/E ratio of -13.58 and a beta of 1.11. Illumina has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a 50 day moving average price of $143.38 and a two-hundred day moving average price of $130.15.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm’s revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 EPS. Analysts expect that Illumina will post 4.11 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.